Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: J Thromb Haemost. 2018 Dec 16;17(1):149–156. doi: 10.1111/jth.14337

Figure 1. The abnormal TVRB in hemophilia mice is corrected by FVIII treatment.

Figure 1.

A. Bleeding intervals in B6 and FVIIIKO mice differ in the TVRB. F8 refers to FVIIIKO mice. The changes in shading denote points of clot disruption. Note persistent bleeding following few disruptions in F8 mice #2, #3 and #5. B. Dose-response of rFVIII treatment in FVIIIKO mice in the TVRB. The number of clot disruptions in 15 min is plotted versus the estimated plasma rFVIII levels following infusion (p<0.0001). Statistical comparison of mouse groups treated to various FVIII levels versus FVIIIKO mice receiving the buffer control (0%): 5%, not significant; 10%, p<0.05; 20%, 35%, 50%, and 100%, p<0.001.